Sen, Triparna <br/><br/>
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.  [electronic resource] 

 -  Cancer discovery  05 2019 
 - 646-661 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2159-8290 
<br/><br/><label>Standard No.: </label>10.1158/2159-8290.CD-18-1020  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Apoptosis--drug effects<br/>B7-H1 Antigen--antagonists & inhibitors<br/>CD8-Positive T-Lymphocytes--drug effects<br/>Cell Proliferation--drug effects<br/>DNA Damage<br/>Female<br/>Humans<br/>Interferon Regulatory Factor-3--genetics<br/>Lung Neoplasms--drug therapy<br/>Lymphocyte Activation--drug effects<br/>Membrane Proteins--genetics<br/>Mice<br/>Mice, Nude<br/>Phthalazines--pharmacology<br/>Piperazines--pharmacology<br/>Poly(ADP-ribose) Polymerase Inhibitors--pharmacology<br/>Protein Kinase Inhibitors--pharmacology<br/>Protein Serine-Threonine Kinases--genetics<br/>Pyrazines--pharmacology<br/>Pyrazoles--pharmacology<br/>Random Allocation<br/>Small Cell Lung Carcinoma--drug therapy<br/>T-Lymphocytes, Cytotoxic--drug effects<br/>Tumor Cells, Cultured<br/>Xenograft Model Antitumor Assays